MissionIR would like to highlight CytRx Corp. (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology. The company’s pipeline is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. The Company also has rights to two additional drug candidates, tamibarotene and bafetinib.
In the company’s news,
Seeking Alpha yesterday published the following article featuring CytRx: http://seekingalpha.com/article/1700372-cytrx-corporation-remains-an-undiscovered-opportunity-inthe-cancer-space?source=yahoo#comments_header
Released On: 4/8/2016
Views: 3868
Released On: 4/7/2016
Views: 4619
Released On: 3/31/2016
Views: 3607
Released On: 3/24/2016
Views: 2942
Released On: 3/17/2016
Views: 2498
Released On: 3/11/2016
Views: 2343
Released On: 3/4/2016
Views: 2646
Released On: 3/3/2016
Views: 2335
Released On: 2/23/2016
Views: 3694
Released On: 2/12/2016
Views: 2693
Released On: 2/10/2016
Views: 2412
Released On: 2/9/2016
Views: 2566
Released On: 1/20/2016
Views: 4350
Released On: 1/14/2016
Views: 4812
Released On: 1/5/2016
Views: 3040
Released On: 12/18/2015
Views: 9375
Released On: 12/9/2015
Views: 2815
Released On: 12/3/2015
Views: 3257